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Background: The prognostic value of evoked potentials (EPs) in multiple sclerosis (MS) has not been fully
established. The correlations between the Expanded Disability Status Scale (EDSS) at First Neurological Evaluation
(FNE) and the duration of the disease, as well as between EDSS and EPs, have influenced the outcome of most
previous studies. To overcome this confounding relations, we propose to test the prognostic value of EPs within an
appropriate patient population which should be based on patients with low EDSS at FNE and short disease
duration.
Methods: We retrospectively selected a sample of 143 early relapsing remitting MS (RRMS) patients with an
EDSS < 3.5 from a larger database spanning 20 years. By means of bivariate logistic regressions, the best predictors
of worsening were selected among several demographic and clinical variables. The best multivariate logistic model
was statistically validated and prospectively applied to 50 patients examined during 2009–2011.
Results: The Evoked Potentials score (EP score) and the Time to EDSS 2.0 (TT2) were the best predictors of
worsening in our sample (Odds Ratio 1.10 and 0.82 respectively, p=0.001). Low EP score (below 15–20 points), short
TT2 (lower than 3–5 years) and their interaction resulted to be the most useful for the identification of worsening
patterns. Moreover, in patients with an EP score at FNE below 6 points and a TT2 greater than 3 years the
probability of worsening was 10% after 4–5 years and rapidly decreased thereafter.
Conclusions: In an appropriate population of early RRMS patients, the EP score at FNE is a good predictor of
disability at low values as well as in combination with a rapid buildup of disability. Interestingly, an EP score at FNE
under the median together with a clinical stability lasting more than 3 years turned out to be a protective pattern.
This finding may contribute to an early identification of benign patients, well before the term required to diagnose
Benign MS (BMS).
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In the neuroimaging era the role of evoked potentials as
diagnostic tools has been greatly diminished. This led
many authors to explore how Evoked Potentials (EPs)
could still be useful as predictors of clinical disability in
multiple sclerosis (MS) [1-11]. Part of the recent litera-
ture addressed this problem from a multivariate para-
metric perspective by looking at the absolute latencies of
multimodal EPs [6,7,10,11], whereas in another group of
studies individual EPs measures were first transformed
into an ordinal summary score (the EP score) [2-5,8,9].
Given that different EP scores as well as different statis-
tical approaches have been proposed, it is perhaps not
surprising that a general consensus over both method-
ology and results is still to be found. A question strictly
confined to the choice of the best EP score or the best
statistical model is for whom the prediction is most ap-
propriate. Some studies have assessed the predictive
value of the EP score by selecting patients with long dis-
ease duration and a moderate to severe clinical disability
at First Neurological Evaluation (FNE) [2,3,5], while
others have enrolled patients with short disease duration
and low clinical disability at FNE [2,4]. The definition of
the appropriate patient population is decisive for the re-
lation between clinical and subclinical variables, e.g. high
values of EP score are more likely to be correlated with
high values of EDSS, thus the prediction of disability
could be automatically improved in a patient population
with a large percentage of secondary progressive MS
courses; however, the clinical utility of this choice is
questionable because the interest in predicting worsen-
ing in patients who are already significantly impaired is
low.
Our aim was to evaluate the predictive value of the EP
score first by determining how an appropriate patient
population should be defined, and then by assessing the
performance of the EP score in a multivariate logistic re-
gression analysis. As the EP score summarizes the quan-
titative information of different EP modalities, it is an
optimal tool to evaluate the overall subclinical impair-
ment of MS patients. By analyzing its performance
within an appropriate patient population it should be
possible to better evaluate the unbiased ability of this
score to predict worsening in MS. In particular, the iden-
tification of a group with a low risk of worsening may
contribute to an early identification of putative benign
MS patients [12].
Methods
Patients
A total of 143 MS patients, who were referred to our
centre (Scientific Institute S. Maria Nascente, don Gnoc-
chi Foundation, Milan, Italy) during the period 1989–
2009 for clinical, neuroimaging and neurophysiologicalassessments, were retrospectively selected from our clin-
ical database. Inclusion criteria for this study were: (1) a
diagnosis of Relapsing Remitting MS (RRMS) using
Poser [13] and McDonald criteria [14]; (2) at least one
complete EPs evaluation performed at FNE (F_EP score)
including Visual (VEP 30’ and 15’), auditory (BAER) and
somatosensory (SEP lower limbs LL and upper limbs
UL) evoked potentials; (3) EDSS at FNE (F_EDSS) lower
than 3.5 points assessed by the same trained neurologist
using the pre-neurostatus version; (4) at least 2 EDSS
follow-ups before the last assessment (5) last EDSS
(L_EDSS) and last EPs (L_EP score) assessments for all
patients during 2008–2009. Additionally, it has been
possible to measure the time between FNE and EDSS
2.0 (TT2) in 65% of the patient population with F_EDSS
below 2.0. Thirty-one patients were defined as benign
MS according to the last accepted criteria, i.e. EDSS ≤
2.0 for at least 10 years [12].
At FNE, 10 patients (7%) were receiving immunomo-
dulatory treatments and 16 (11%) immunosuppressive
treatment; however, patients with and without treat-
ments did not differ in terms of EDSS, EP score and dis-
ease duration at FNE.
Patients with incomplete EP tests or missing EDSS
values, as well as patients with EDSS ≥ 3.5 at the FNE
were not included. EDSS was considered only if assessed
during periods of clinical stability.
This study has been approved by the ethics committee
of the Scientific Institute S.Maria Nascente of Milan and
has been performed in accordance with the ethical stan-
dards of the declaration of Helsinki.
The EP score
VEP, BAER ,SEP-LL and SEP-UL were recorded accord-
ing to recommended standardized protocols [15]. SEPs
were obtained by electrical stimulation of the median
nerves at the wrists, and of the posterior tibial nerves
at the ankles. Latencies of the main peripheral, spinal
and cortical components were measured along with the
latency difference N9-N20 and amplitude difference
N20-N25 for median nerve SEP, the latency difference
N19-P37 and amplitude difference P37-N45 for tibial
nerve SEP. VEP to black and white pattern-reversal
stimulation with checks of 30 and 15 minutes of arc
were recorded over Oz of the 10–20 international sys-
tem, with Fz as the reference. The latency of the P100
component and the amplitude difference N75-P100 were
measured. BAER to clicks at 70 dB above subjective
threshold with contralateral white noise masking were
recorded at the CZ electrode referred to the ipsilateral
and contralateral ears. The latency of the main peaks I,
III and V, the inter-peak latencies (I-III, III-V and I-V)
and the I:V amplitude ratio were measured. Stimulation
and recording were carried out using commercial
Table 1 Demographical and clinical variables
Variable Mean±SD Median (IQR)
Age at FNE 31.9 ± 8.7 31 (25–38)
Time from first symptom to FNE 4.5 ± 4.6yrs 3 (1–7)yrs
Time from FNE to 2009 10.5 ± 4.6yrs 11(6.5-14)yrs
F_EP score 7.6 ± 8.5 5 (2–11)
F_EDSS (<3.5) 1.3 ±0.9 1.5 (1–2)
TT2 6.5 ± 7.7 3( 0–11)
L_EDSS 2.7 ± 1.7 2.5 (1.5-3.5)
IQR = Inter Quartile Range; FNE = first neurological evaluation; F_EP score= EP
score at first neurological evaluation; F_EDSS = EDSS at first neurological
evaluation; L_EDSS = last EDSS assessed during 2009; TT2=time to EDSS 2.0;
Yrs=years. % women = 79 (n=113).
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XLTEKW Protektor) by the same experienced techni-
cians. As abnormalities were quantified separately for
each modality (VEP 30’, VEP 15’, BAEP, SEP LL, SEP
UL), according to a six-point graded scale drawn from
the work of Jung et al. (0 = normal; 1 = pathological side
difference of latency; 2 = latency above the normal range
but below 1.1 x upper limit, or >50% side difference of
amplitude; 3 = latency 1.1-1.3 x upper limit; 4 = latency
above 1.3 x upper limit; 5 = absent EP component), the
worst possible score summarizing all the EPs modalities
was 50 (5 points x 2 sides x 5 EP modalities) [4].
Statistics
First, the associations of the outcome variable L_EDSS
with EP score, F_EDSS and TT2, were analyzed by the
Spearman’s rank correlation coefficient. In addition, the
associations between L_EDSS and other clinical charac-
teristics at FNE were examined. Receiver operating char-
acteristic curves (ROC) for the clinical variables (EP
score, EDSS, TT2) were used to predict whether clinical
worsening, defined as crossing the threshold of EDSS
3.5, occurred before 2008–2009. The area under the
curve (AUC) and the 95% confidence intervals (CI) for
each variable were also considered. In line with C.
Renoux [16], an EDSS of 3.5 was selected as a turning
point between low and moderate/severe disability since
it allows a more conservative approach than higher
thresholds (e.g. 4.0 or 6.0) by decreasing false negatives.
A change of 1.0 EDSS point is another measure of
worsening proposed in literature [5,6]; however, in a
clinical sample with random follow-ups a progression of
1.0 or 1.5 EDSS points could be more easily lost than in
an experimental sample with follow up visits at fixed
intervals. Moreover, this choice would force us to con-
sider changes between different EDSS steps as equal (e.g.
0–1.0 and 2.0-3.0).
Second, we sought to ascertain whether a combination
of EP score and other clinical variables could improve
the prediction of clinical worsening by using a multivari-
ate logistic regression analysis. To identify other poten-
tial predictors of clinical worsening we performed a
backward selection starting with a model that contained
all demographical (age at FNE, gender, disease duration)
and clinical variables (F_EDSS,F_EP score, TT2) with p<
0.2 on bivariate logistic regressions. In the resulting
multivariate logistic regression model, variables with p-
values ≥ 0.2 were eliminated leaving the F_EP score,
F_EDSS and TT2 as the best predictors of disability.
Given the multicollinearity between F_EDSS and TT2,
which cast doubt on their independence, two models
were tested: (model 1) with F_EP score and TT2 and
(model 2) with F_EP score and F_EDSS. The final choice
of Model 1 (hereinafter referred to as “the model”) wasbased on likelihood ratio chi-squares, Akaike’s informa-
tion criteria (AIC) and Bayesian information criteria
(BIC). ROC curves were used again to assess the best
cut off point of the model in terms of sensitivity and
specificity, and the resulting AUC was compared with
those of the previous bivariate ROC analyses. The distri-
bution of predicted probabilities for each variable was
evaluated by plotting each regressor against the prob-
ability of reaching EDSS 3.5. To better assess how final
variables might interact, the predicted probabilities were
also analyzed by dividing the whole sample by the me-
dian value of the variable TT2. The EP scores of the
resulting two subgroups (i.e. patients below and above
the median of TT2) were plotted against the probability
of reaching EDSS 3.5 to assess if the predicted probabil-
ity curves had a similar shape (i.e. no effect of TT2 sub-
groups over the EP score) or if differences occurred
between subgroups. The same procedure was used after
dividing the whole sample by the median value of the EP
score.
Third, the model was validated by using a non-
parametric bootstrap analysis and it was prospectively
applied to a group of 50 patients (11 follow up patients
and 39 newly selected cases) examined during 2009–
2011 to show its practical utility.
Results
The demographical and clinical characteristics of the
143 MS patients are shown in Table 1.
Spearman correlation coefficients (ρ) between EP score
and EDSS ranged from weak (0.27; p<0.001) at FNE to
moderate (0.41; p<0.0001) at the time of the last assess-
ment (L_EDSS). Likewise, TT2 was strongly correlated
with F_EDSS (−0.73; p<0.0001) and moderately with
L_EDSS (−0.55; p<0.0001). The correlation between
F_EP score and TT2 was weak (−0.25; p<0.01) and none
of the correlations between L_EDSS and the demogra-
phical variables were significant. To verify whether the
variability of F_EDSS and of the time elapsed from the
first symptom to FNE could have influenced the
Table 3 The logistic regression model
Parameter β-Estimate Odds ratio Standard Error p-value
Model 1:
Intercept −0.8987 - 0.3500 0.010
EP score 0.0955 1.10 0.0282 0.001
TT2 −0.1990 0.82 0.0587 0.001
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the correlations stratifying cases by the median EDSS
value (1.5) and by the interval between disease onset
and the first neurophysiologic evaluation [5] (see
Table 2 for details).
We found a statistically significant correlation between
the L_EP score and L_EDSS in both subgroups, while at
FNE only the subgroup with an EDSS > 1.5 was signifi-
cantly correlated with F_EP score (Table 2). Forty-eight
patients had an EPs test within 2 years from disease
onset, 55 after 2–6 years, and 40 after more than 6 years.
We found that the correlation between the L_EP score
and L_EDSS was significant in all three subgroups, while
at FNE the correlation between the F_EP score and
F_EDSS was significant only for the longest duration
subgroup (Table 2).
The predictive power of the F_EP score, F_EDSS and
TT2 was analyzed by means of ROC curves: AUC for
the F_EP score was 0.72 (95 % CI: 0.63-0.82), 0.71 for
F_EDSS (95% CI: 0.61-0.81), and 0.74 for TT2 (95% CI:
0.66-0.82).
Our backward selection procedure for the multivariate
logistic regression resulted in the following prediction
model (Table 3):
logP Y ¼ 1 x1 . . . xnj Þ ¼ 0:899þ 0:095  EPscore½ ð
0:199  TT2½ 
where n=2 and LRχ2 ¼ 45:84 p > χ2 ¼ 0:0000ð Þ
All the diagnostics of the logistic regression model
were run to check for possible errors of specification,
multicollinearity and influential observations. Predic-
tions showed a moderate correlation with the observed
values (Spearman rank ρ = 0.495, p<0.0001). The model
was tested against the corresponding bivariate models
including either TT2 or F_EP score to evaluate how the
addition of each variable contributed to the model fit-
ting. The goodness of fit was significantly higher in both
cases (likelihood ratio χ² = 22.69, p<0.0001 for the inclu-
sion of TT2 and likelihood ratio χ² = 14.49, p=0.0001 forTable 2 Correlations between EP score and EDSS
Variable
ρ
(a)F_EDSS
≤ 1.5(n=94,EP score 6.4±7.5,Disease duration 3.7±4.1) 0.14
>1.5(n=49, EP score 10±9.8,Disease duration 5.9±5.1) 0.39
(b)Interval between MS onset and FNE
< 2 yrs (n=48) 0.08
2-6 yrs (n=55) 0.20
> 6 yrs (n=40) 0.47
(a) patient population divided for the median EDSS; (b) patient population stratified
p-values are corrected for multiple comparisons; F_EDSS= first EDSS assessment.the inclusion of EP score); indeed the AUC was 0.8135
(95% CI 0.74 – 0.88), better than the AUCs of the EP
score, F_EDSS and TT2 taken individually (p <0.02).
The sensitivity and specificity at different cut-off
points for the prediction of clinical worsening are shown
in Figure 1.
The cut-point for the predicted threshold of EDSS 3.5
was 0.31, corresponding to the highest sensitivity (0.738)
and the highest specificity (0.693). The resulting index of
accuracy (Youden) was 0.43.
The predicted probabilities of the model are plotted in
Figure 2 and 3; it appears that the probability to reach
EDSS 3.5 increases as the F_EP score approaches the
highest values of the scale; over 25 points, worsening is
highly probable (Figure 2). On the other hand, the prob-
ability decreases as the length of time (years) to reach
EDSS 2.0 increases; over 12 years, worsening is highly
improbable (Figure 3).
A more detailed picture was obtained by dividing the
whole sample by the median value of each variable (3
years for TT2 and 5 points for EP score), as detailed in
the Methods. Accordingly, Figure 4 shows that the TT2
subgroups (i.e. above and below the median of TT2)
show diverging probability curves below 20–15 points,
whereas at higher EP values the curves tend to overlap.
Likewise, the EP score subgroups (i.e. above and below
the median of EP score) show diverging probability
curves associated with a length of time to EDSS 2.0
shorter than 3–5 years, while at longer TT2 values the
curves tend to overlap (Figure 5).
It is worth clarifying at this point that these results
were obtained by arbitrarily ending the study in 2009.At FNE At last follow-up
p-value ρ p-value
0.15 0.33 0.002
0.0114 0.41 0.0064
0.55 0.46 0.0027
0.13 0.34 0.0297
0.006 0.46 0.009
for the interval between onset and the first neurological evaluation (FNE);
Figure 1 ROC curve resulting from the logistic regression model. The area under the curve (AUC = 0.81) shows the sensitivity and specificity
corresponding to different cut-off points of the prediction of clinical worsening (defined by patients reaching the threshold of EDSS 3.5). The best
cut-off point defined by the maximum of Youden’s index corresponds to a sensitivity of 0.738 and a specificity of 0.693.
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extended up to our longest retrospective analysis (20
years, from 1989 to 2009); however, as the time from
FNE to the end of the study was greatly variable among
our patients, the actual prediction span is lower than 20
years (10 years on average, see Table 1). In order to over-
come this limitation, data from 11 patients (7.7% of the
original sample), who were followed up for less than 5
years between FNE and the study endpoint, were pooledFigure 2 Distribution of predicted probabilities for EP score and TT2.
how the predicted probabilities (PP) of clinical worsening are distributed al
of EP values and their corresponding PP is reported below the graph. Shadwith data of 39 new patients examined during 2009–
2011 and used for a prospective assessment of the model
(see Table 4 for details).
Ten of the 11 patients who were reassessed once dur-
ing the prospective follow-up were correctly classified by
the model. The only misclassified case had an F_EP
score (dating back to 1996) of 7 and a F_EDSS of 2.0
resulting in a probability of 0.44, which lies just below
the model cut off and indicates a low probability ofA sampling plot drawn from the logistic regression model showing
ong the EP score scale (with TT2 held constant at the mean). A sample
ed area represents 95% CI.
Figure 3 Distribution of predicted probabilities (PP) for EP score and TT2. A sampling plot drawn from the logistic regression model,
showing how the predicted probabilities of clinical worsening are distributed along the TT2 variable (x-axis = yrs; with the EP score held constant
at the mean). A sample of TT2 values and their corresponding PP is reported below the graph. Shaded area represents 95% CI.
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was still correct in 2009, this patient eventually pro-
gressed to EDSS 3.5 during 2011, i.e. 15 years after FNE.
All the patients with a probability exceeding 0.6 (n= 4/
17) having a mean F_EP score of 25.7 and an F_EDSS
over 2.0 reached the threshold in a variable time span
ranging from 1 to 20 years. On the other hand, patients
with a probability lower than 0.4 (n= 10/17) and a mean
F_EP score of 1.4 did not reach the threshold within a
16 years period; five of them had not reached EDSS 2.0Figure 4 Plot of predicted probabilities (Y-axis) vs. the EP score (X-ax
represents patients with TT2 ≤ 3 yrs. The difference between the curves is
values grow until it eventually becomes negligible at approximately an EPat the time of L_EDSS assessment, while the others had
a mean TT2 of 4.2 years.
Finally, a non parametric bootstrap analysis was car-
ried out to validate the model using the Bias Corrected
and Accelerated (BCA) method in order to estimate the
95% bootstrap confidence interval for each variable (EP
score CI= 0.04 to 0.15 ; TT2 CI= −0.13 to −0.29). Given
that the diagnostic criteria for bootstrap analysis were
fully met (low differences between predicted and
observed regressors coefficients and standard errors,is). The dotted line represents patients with TT2 > 3 yrs; the solid line
largest at the origin of the EP axis and tends to decrease as the EP
score of 20.
Figure 5 Plot of predicted probabilities (Y-axis) vs. TT2 (X-axis). The dotted line represents patients with an EP score ≤ 5; the solid line
represents patients with an EP score > 5. The difference between the curves is largest at the origin of the TT2 axis and decreases as TT2 exceeds
4–5 years.
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preted these results as consistent with a successful pro-
spective validation of the model.
Discussion
The retrospective part of this study aimed to build up
and evaluate a model combining neurophysiologic and
clinical evaluations to obtain a reliable prediction of the
progression of disability in MS patients with particular
attention to the role of evoked potentials. A summary
score considering both abnormalities of latencies as well
as of morphology and of amplitude symmetry of the
principal EP components [4] was utilized as input in the
analyses to assess the prognostic value of EPs. Since
none of the recent works have compared the different
EP score systems which have been proposed in the last
decade, consistent with a previous work of our group
[8], we chose the scoring system preserving most of the
EP information [4]. The latter allows a maximum of 6
points for each side and for any of 5 EP modalities, as
opposed to only 4 points in Leocani et al. [3] and 3 in
Kallman et al. [2].Table 4 Results of the prospective study
prospective study F_EP score (med; range) F_EDSS (med; ra
11 pts. 5; 0-25 1.5; 0-3
6 pts. 1.5; 0-37 2.0; 0-3
33 pts. 6; 0-28 1.5; 0-3
11 pts. = 11 patients drawn from the original patient population who returned for a
examinations during 2009–2011; 33 pts.= 33 patients with only 1 EPs and EDSS ass
n/ms = number of patients/ number of patients misclassified by the model; F_EP sc
neurological evaluation.At FNE, our patients showed a correlation between EP
score and EDSS which was lower compared to that
reported by Invernizzi et al., Leocani et al., and Kallman
et al.’s group 2 [2,3,5], but greater than that reported by
Jung et al. and Kallman et al.’s group 1 [2,4]. As shown
in Figure 6, this apparent inconsistency is likely due to
two important factors. First, the correlation between
EDSS and EP score depends on the severity of disability
already present at FNE insofar as the correlation tends
to increase as disability builds up (Figure 6, from 1 to 6).
As already suggested by Leocani et al. [3], this is a pat-
tern toward a ceiling effect that results from the inclu-
sion of subjects with more severe disability and a
progressive disease course.
Second, disease duration also impacts the degree of
clinical disability and, consequently, the correlation be-
tween clinical and subclinical measures. This is clearly
shown in Figure 6 (x-axis) where the correlation be-
tween EDSS and EP score tends to grow as the disease
duration increases because so does the F_EDSS. The ef-
fect of the disease duration showed up more clearly
when we analyzed the correlation between F_EP scorenge) Pr.<0.4(n/ms) Pr.0.4-0.6 (n/ms) Pr.≥0.6(n/ms)
6/0 3/1 2/0
4/0 - 2/0
26/. 4/. 3/.
dditional EDSS assessment during 2010–2011; 6 pts. = 6 patients with 2
essment during 2009–20011. Med = median; Pr. = probability of worsening;
ore = EP score at first neurological evaluation; F_EDSS= EDSS at first
Figure 6 Correlations between EDSS and EP scores in the last 6 years literature. The correlations between EDSS and EP scores reflect the
researchers’ choice of patients selection criteria. 1: Kallmann et al. 2006 [2] group 1, F_EDSS =2.0, range (0–4). 2: Jung et al. 2008 [4] F_EDSS = 1.5,
range(0–3). 3: this study, F_EDSS = 1.5, range(0–3). 4: Leocani et al. 2006 [3], F_EDSS = 3.5, range (1–8). 5: Invernizzi et al. 2011 [5], F_EDSS = 3.0,
range(0–6.5). 6: Kallmann et al. 2006 [2] group 2, F_EDSS =3.5, range(0–7).F_EDSS= first EDSS assessment.
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value of F_EDSS (Table 2). The correlation was statisti-
cally significant only in the higher F_EDSS subgroup. In
contrast to Invernizzi et al. [5], this finding suggests that
the difference in disease duration between the 2 sub-
groups thus identified (3.7 yrs, 5.9 yrs; p=0.005) was de-
cisive. Moreover, when we stratified by the time from
the first symptom to FNE, only patients assessed more
than 6 years after disease onset showed a moderate cor-
relation (ρ=0.47) between the F_EP score and F_EDSS,
while at the last follow-up the correlations increased ap-
proximately to the same extent also in the two
remaining subgroups. These findings are in line with
Kallmann et al. [2] who found a significant correlation
between F_EDSS and F_EP score in patients with a long
disease duration at FNE (mean 9.6 years), while in the
group with a shorter disease duration (mean 1.2 years)
the correlation was not significant.
Moreover, Hughes et al. [17] recently confirmed that
the prediction at 5 and 10 years based on the EDSS is
higher when applied to patients with 4–5 years of dis-
ease duration. Findings from other fields of research
such as MRI are also affected by similar choices: in Onu
et al.’s work [18], the authors admitted that significant
correlations between MRI and EDSS depended on the
inclusion of patients with high EDSS (0–5.5) and a long
disease duration (mean = 9.3 years), whereas in a work
by Metwalli et al. [19], who studied patients with lower
EDSS (0–3) and shorter disease durations (mean = 1.2
years), no significant correlations were found. Though it
is certainly true that sampling the entire range of the
EDSS can lead to better coefficients whatever thecorrelate [20], the opportunity of such a choice is ques-
tionable as the most critical medical decisions are those
made in the early phases of MS.
An early MS diagnosis, in addition to being preferred
by MS patients [21], generally also imply low F_EDSS
scores; indeed, as recently reviewed by C. Renoux [16], a
shorter time from onset to moderate disability (DSS 3.0
or 4.0) has been associated with a faster rate to severe
disability; moreover, worsening in MS becomes more
common after EDSS 4.0 [17], further remarking the im-
portance to include only patients with low F_EDSS if
useful clinical predictions are to be made. Accordingly,
we could confirm that the variable TT2 represents the
early progression of the disease and can predict further
worsening. Although it was set at the value of zero for a
part of our patient population (35% already with EDSS
2.0 at FNE), the variable TT2 was significant both in bi-
variate and multivariate analyses and also a significant
correlation with L_EDSS (−0.55; p < 0.0001) was rather
stable. It is worth reminding here that a threshold of
EDSS 2.0 was also recently applied to the definition of
BMS (Benign Multiple Sclerosis) together with a disease
duration equal or longer than 10 years [12].
Consequently, a logistic regression model including
the F_EP score as well as the TT2 variable was applied
to a sample of 143 RRMS patients having a mean disease
duration of 4.5 years and a mean F_EDSS of 1.3. The
aim of the model was to predict the progression of dis-
ability defined as the risk of reaching the threshold of
EDSS 3.5 [16,17]. Likelihood ratio tests successfully
assessed the relevance of the overall model (likelihood
ratio χ² = 45.84, p<0.0001) and of TT2 and EP score
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hood ratio χ² = 14.49, p=0.0001 respectively). The multi-
variate approach was supported also by a significant
improvement of the AUC compared with that previously
obtained with single variables (AUC: 0.8135, p<0.02). A
first consideration is that the EP score has a strong prog-
nostic value when EDSS 2.0 is reached in 3–5 years from
FNE (Figure 5), since the difference in the probabilities
of further worsening between the two subgroups
(i.e. above or below the median value of the EP score) is
nearly 30%. This means that when TT2 is short, the
probability of worsening switches from 30% to over 60%
by having , for example, 4 or 8 points of the EP score
respectively.
On the other hand, high EP scores (over 20–25 points)
or a long time to reach EDSS 2.0 (over 10–15 years) were
not associated with very different probabilities of worsen-
ing among the subgroups obtained by dividing the whole
sample by the median value of TT2 (Figure 4) or of the
EP score (Figure 5). First, this indicates that data of
patients with severe subclinical damage (i.e. high EP
scores) and patients with progressive MS courses should
not be considered for predictive models if the aim is an
early identification of different patterns of progression;
indeed, patients with these characteristics are well known
to be candidates to clinical worsening and no prediction
is needed. Second, patients with long disease duration at
FNE have to be excluded if long disease duration is not
associated to clinical stability. We have shown (Figure 6)
that since mean disease duration is related to mean
EDSS, worsening is to be expected; by the same token, if
a long disease duration is associated to clinical stability,
like in BMS, further worsening becomes unlikely and
again no prediction is really needed.
The EP score and TT2 have the greatest utility when
their values are able to show different patterns of wor-
sening. By dividing our sample in 4 groups, namely (a)
high F_EP score + short TT2 (b) high F_EP score + long
TT2; (c) low F_EP score + short TT2 and (d) low F_EP
score + long TT2, we showed that our model can iden-
tify separate patterns. Groups (a) and (b) have in com-
mon a high subclinical impairment and therefore are
candidates to clinical worsening whatever the conversion
time to clinical disability (as shown by overlapping solid
and dotted lines approximately in the last 30 values of
the x-axis in Figure 4). On the other hand, in the case of
groups (c) and (d) characterized by a low EP score, the
difference in TT2 determines a higher probability of
worsening to group (c) than to group (d) (solid and dot-
ted lines in the first 5 values of the x-axis in Figure 5). A
high subclinical impairment (i.e. high EP score) is likely
to reflect a massive attack of MS to the central nervous
system and the probability that the adaptive brain
responses will not be sufficient to compensate thedamages; thus the disability will likely worsen whatever
its speed of progression. On the other hand, a low sub-
clinical impairment could enable compensation pro-
cesses. In this case, even small differences in EP score
and speed of disability progression (TT2) may identify
patients in whom compensatory processes can be suc-
cessfully enabled, like in benign MS [21,22]. Accordingly,
Figure 5 shows that as the time from FNE to EDSS 2.0
increases, the chance of further worsening decreases fol-
lowing two probability curves depending on the F_EP
score; when the EP score is above the median value, the
probability takes about 15 years without clinical progres-
sion to become negligible (<10%). On the other hand,
when the EP score is below the median value, the prob-
ability of further worsening approaches 0 after only 4–5
years without clinical progression. This last finding gives
the EPs a possible role in the debate concerning the
definition of BMS [23-25]. According to an earlier
EDSS-based definition of BMS a patient with a final
EDSS ≤ 3.0 was declared as “benign” after 15 years from
onset [26]. Recently, the diagnostic criteria for BMS have
been redefined as an EDSS score ≤ 2.0 after a disease
duration of at least 10 years [12]. However, the debate
has been reopened by recent reports which state that
cognitive impairment was detected in 45% of a large
group of patients fulfilling traditional criteria for BMS
[27], but also by the suggestion that neuropsychological
tests can contribute to a more accurate identification of
“true” BMS [23,27-29]. In this study we provide evidence
that the EP score may be an interesting covariate for the
definition of BMS. Indeed, the risk of worsening is al-
most null in patients with a F_EP score lower than 5
points and a time to EDSS 2.0 of 4 or more years (dotted
curve in Figure 5, representing 22% of the patient popu-
lation). As shown in Figure 5, our results are in line with
the earlier and last stringent definition of BMS because
the probability goes under about 10% after 10 years and
under 5% after 15 years; furthermore, the dotted curve
indicates that for patients with low F_EP score, the risk
becomes less than 10% after about 4–5 years if the EDSS
remains below 2.0, and already tends to zero between 5
and 10 years. This finding suggests that the information
drawn from the EPs could substantially improve the sen-
sitivity and decrease the time needed to make a diagno-
sis of BMS according with the last criteria [12]. We
acknowledge however, that the failure to include the
motor evoked potentials - not available for the entire pa-
tient population and which have been shown to be sig-
nificantly correlated to the EDSS score [2-7,9-11] - and
other potentially useful covariates such as neuropsycho-
logical tests [27-29] could have reduced the accuracy of
our prediction. It is our belief that a protocol combining
all the variables of interest for the prediction of disability
should be encouraged.
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tions based on EPs do not seem to be influenced by
immunomodulatory treatments. Vucic S [31] suggested
that this fact may imply an element of disease irreversi-
bility already at the time of initial assessment [31]. If it
was true, it would be advisable to reconsider the thera-
peutic and monitoring approach to BMS in the light of
early predictions based on appropriate multivariate
models. This also appears to support the need for fur-
ther studies employing sensory and motor EPs together
with neuropsychological tests to provide a more reliable
prediction of BMS.
In the prospective part of this work we evaluated the
risk of progression to EDSS 3.5 by applying our model
to data partially obtained during the period 2009–2011.
The outcome was correctly predicted by the model in 16
of 17 patients who completed the two years follow-up;
the subject who was misclassified received a prediction
close to 0.5. To improve the usefulness of the model and
reduce false negatives, we are paying special attention to
patients with a predicted probability in the range be-
tween 0.4 and 0.6. Four of the 33 patients who were
assessed only once during 2009–2011 fulfilled this re-
quirement and are now being closely monitored.
Conclusions
In conclusion, we showed that a logistic regression
model combining clinical and neurophysiologic data col-
lected at FNE from early RRMS patients can be a reli-
able tool to identify patterns of prognosis in everyday
clinical practice. Furthermore, we have been able to
identify a pattern that could improve the definition of
BMS using both EP score and EDSS progression. We
have also discussed why a model centered on an appro-
priate patient population, i.e. RRMS with low disease
duration and low F_EDSS, is to be preferred to models
derived from samples with higher disease duration,
higher F_EDSS and progressive MS courses which lead
to more accurate but less practical predictions. We
strongly believe that heuristic rather than esthetic results
are to be pursued and that the real challenge arena for
prediction models in MS is the early phase of the disease
when divergence among clinical and neurophysiologic
measures is still important, allowing the EP score to ex-
press its unbiased potentiality.
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